Literature DB >> 20554167

Molecular targeted therapies for patients with refractory thyroid cancer.

C Chougnet1, M Brassard, S Leboulleux, E Baudin, M Schlumberger.   

Abstract

The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial. Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20554167     DOI： 10.1016/j.clon.2010.04.008

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


  5 in total

1.  Synthesis and in vivo evaluation of an (18)F-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography.

Authors:  Simone Maschauer; Kristin Michel; Philipp Tripal; Katrin Büther; Torsten Kuwert; Otmar Schober; Klaus Kopka; Burkhard Riemann; Olaf Prante
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-09-19

Review 2.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

3.  Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib.

Authors:  Shinya Suzuki; Ai Horinouchi; Shinya Uozumi; Chihiro Matsuyama; Hayato Kamata; Asumi Kaneko; Masakazu Yamaguchi; Hiroshi Okudera; Makoto Tahara; Toshikatsu Kawasaki
Journal:  SAGE Open Med       Date:  2020-06-12

4.  Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience.

Authors:  Lucia Brilli; Cristina Dalmiglio; Tania Pilli; Filomena Barbato; Fabio Maino; Marco Capezzone; Alessandra Cartocci; Maria Grazia Castagna
Journal:  J Clin Med       Date:  2021-01-20       Impact factor: 4.241

5.  SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.

Authors:  Elisa Stellaria Grassi; Valeria Vezzoli; Irene Negri; Árpád Lábadi; Laura Fugazzola; Giovanni Vitale; Luca Persani
Journal:  Oncotarget       Date:  2015-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.